Prostaglandins in the eye: Function, expression, and roles in glaucoma.
Prostaglandins in the eye: Function, expression, and roles in glaucoma. Ophthalmic Genet. 2016 Apr 12;:1-9 Authors: Doucette LP, Walter MA Abstract Prostaglandins are small pro-inflammatory molecules derived from arachidonic acid that play roles in a multitude of biological processes including, but not limited to, inflammation, pain modulation, allergies, and bone formation. Prostaglandin analogues are the front-line medications for the treatment of glaucoma, a condition resulting in blindness due to the death of retinal ganglion cells. These drugs act by lowering intraocular pressure (IOP), a major risk factor for glaucoma. The currently used prostaglandin analogues (latanoprost, bimatoprost, tafluprost, and travoprost) mimic PGF2 and target one of the prostaglandin receptors (FP), though research into harnessing the other receptors using compounds like Sulprostone (EP3 receptor), or Iloprost (IP receptor) are currently ongoing. In this review, we summarize the research into each of the prostaglandin molecules (PGD2, PGE2, PGF2, PGI2, TXA2) and their respective receptors (DP, EP1, 2, 3, 4, FP, IP). We examine the modes of action of each of these receptors, their expression, their role in aqueous humour production and outflow within the eye, as well as their roles as medications for the treatment of glaucoma. PMID: 27070211 [PubMed - as supplied by publisher]
History of TBI tied to 52 percent increased odds of prescription opioid use, 65 percent increased odds of prescription opioid misuse
Conclusion Results may assist clinicians in aiming exercise programs toward increasing hip and potentially core strength, thus improving balance to promote better mobility for individuals with a lower-limb amputation.
Conclusion The results show varying benefits of the microprocessor- and hydraulic-controlled prosthetic components over fixed-ankle ESAR and FK feet, based on both performance-based and patient-reported outcome measures. Further studies are needed to fully evaluate these benefits in larger sample sizes.
Genteel's glucose testing product is distributed worldwide.
The 33-year-old in Texas sought medical help after suffering pain in his testicles for five days, but had been passing a 'substantial amount' of semen and urine from his anus for two years.
A new gene therapy company attempting to commercialize the research of Penn Medicine's Dr. Jean Bennett launched Wednesday in North Carolina with $19 million in seed capital. The company, Opus Genetics, is the first spinout company internally conceived and launched by the Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness. The fund was created to further the foundation's mission of backing research to prevent, treat and cure retin al degenerative diseases. Opus…
Condition: Low Back Pain Interventions: Device: ReOxy; Device: Sham ReOxy Sponsor: Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine Recruiting
Conditions: Pain, Postoperative; Analgesia Intervention: Procedure: Enema Sponsor: Taipei Medical University Shuang Ho Hospital Completed
Conditions: Pain, Postoperative; Anxiety; Postpartum Complication Interventions: Behavioral: Healing Touch; Other: Control Sponsor: Inova Health System Enrolling by invitation
Conditions: Cancer Pain; Breakthrough Pain Interventions: Drug: Intravenous Infusion; Drug: Sublingual Tablet Sponsor: Seoul National University Not yet recruiting